Zoetis (ZTS) Change in Accured Expenses (2014 - 2026)
Zoetis (ZTS) posted quarterly Change in Accured Expenses of -$234.0 million for Q1 2026, down 13.59% year-over-year from -$270.8 million in Q1 2025, and down 365.91% quarter-over-quarter from $88.0 million in Q4 2025.
Zoetis (ZTS) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Change in Accured Expenses for 13 consecutive years, with -$234.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 13.59% year-over-year to -$234.0 million; the TTM figure through Mar 2026 stood at $57.0 million (up 72.73% YoY), while the FY2025 annual figure was $85.0 million, down 25.44% from the prior year.
- Change in Accured Expenses retreated to -$234.0 million in Q1 2026 per ZTS's latest filing, from $88.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $124.0 million in Q3 2024 and bottomed at -$234.0 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged -$8.7 million across 5 years, with a median of $32.0 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 208.33% — and 2024, when it surged 825.0%.
- Zoetis' Change in Accured Expenses stood at $47.0 million in 2022, then surged by 100.0% to $94.0 million in 2023, then slipped by 17.02% to $78.0 million in 2024, then advanced by 12.82% to $88.0 million in 2025, then plunged by 365.91% to -$234.0 million in 2026.
- Business Quant data shows ZTS's Change in Accured Expenses at -$234.0 million in Q1 2026, $88.0 million in Q4 2025, and $101.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 41.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.00 Mn |
| Jun 30, 2026 | 142.00 Mn |
| Mar 31, 2026 | -234.00 Mn |
| Mar 31, 2026 | -234.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Sep 30, 2025 | 101.00 Mn |
| Sep 30, 2025 | 101.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Jun 30, 2025 | 102.00 Mn |
| Mar 31, 2025 | -206.00 Mn |
| Mar 31, 2025 | -206.00 Mn |
| Dec 31, 2024 | 78.00 Mn |
| Dec 31, 2024 | 78.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Jun 30, 2024 | 37.00 Mn |
| Jun 30, 2024 | 37.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Mar 31, 2024 | -125.00 Mn |